About: Human herpes virus co-infection is associated with mortality in HIV-negative patients with Pneumocystis jirovecii pneumonia

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Human herpes virus co-infection is associated with mortality in HIV-negative patients with Pneumocystis jirovecii pneumonia Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Human herpes virus co-infection is associated with mortality in HIV-negative patients with Pneumocystis jirovecii pneumonia
Creator	Jouneau, S Fillatre, P Leroy, H Tattevin, P Minjolle, S Chevrier, S Gacouin, : Gacouin, A Le Tulzo, Y Revest, M Robert-Gangneux, F
Source	PMC
abstract	The purpose of this investigation was to characterize the management and prognosis of severe Pneumocystis jirovecii pneumonia (PJP) in human immunodeficiency virus (HIV)-negative patients. An observational cohort study of HIV-negative adults with PJP documented by bronchoalveolar lavage (BAL) through Gomori–Grocott staining or immunofluorescence, admitted to one intensive care unit (ICU) for acute respiratory failure, was undertaken. From 1990 to 2010, 70 patients (24 females, 46 males) were included, with a mean age of 58.6 ± 18.3 years. The mean Simplified Acute Physiology Score (SAPS)-II was 36.9 ± 20.4. Underlying conditions included hematologic malignancies (n = 21), vasculitis (n = 13), and solid tumors (n = 13). Most patients were receiving systemic corticosteroids (n = 63) and cytotoxic drugs (n = 51). Not a single patient received trimethoprim–sulfamethoxazole as PJP prophylaxis. Endotracheal intubation (ETI) was required in 42 patients (60.0 %), including 38 with acute respiratory distress syndrome (ARDS). In-ICU mortality was 52.9 % overall, reaching 80.9 % and 86.8 %, respectively, for patients who required ETI and for patients with ARDS. In the univariate analysis, in-ICU mortality was associated with SAPS-II (p = 0.0131), ARDS (p < 0.0001), shock (p < 0.0001), and herpes simplex virus (HSV) or cytomegalovirus (CMV) on BAL (p = 0.0031). In the multivariate analysis, only ARDS was associated with in-ICU mortality (odds ratio [OR] 23.4 [4.5–121.9], p < 0.0001). PJP in non-HIV patients remains a serious disease with high in-hospital mortality. Pulmonary co-infection with HSV or CMV may contribute to fatal outcome.
has issue date	2012-08-22(xsd:dateTime)
bibo:doi	10.1007/s10096-012-1730-7
bibo:pmid	22930407
has license	no-cc
sha1sum (hex)	cf249b1259f68e1c79a8e80d5f3fb3c9c0216144
schema:url	https://doi.org/10.1007/s10096-012-1730-7
resource representing a document's title	Human herpes virus co-infection is associated with mortality in HIV-negative patients with Pneumocystis jirovecii pneumonia
has PubMed Central identifier	PMC7102362
has PubMed identifier	22930407
schema:publication	Eur J Clin Microbiol Infect Dis
resource representing a document's body	covid:cf249b1259f68e1c79a8e80d5f3fb3c9c0216144#body_text
is schema:about of	named entity 'Most' named entity 'ETI' named entity 'co-infection' named entity 'trimethoprim-sulfamethoxazole' named entity 'vasculitis' named entity 'observational' named entity 'bronchoalveolar lavage' named entity 'univariate analysis' named entity 'fatal' named entity 'acute respiratory distress syndrome (ARDS)' named entity 'mortality' named entity 'Not' named entity 'receiving' named entity 'males' named entity 'received' named entity 'prophylaxis' named entity 'patient' named entity 'age' named entity 'HIV-negative' named entity 'Endotracheal intubation' named entity 'HSV' named entity 'intensive care unit' named entity 'PJP' named entity 'Physiology' named entity 'staining' named entity 'cytotoxic drugs' named entity 'bronchoalveolar lavage' named entity 'cytomegalovirus' named entity 'ARDS' named entity 'solid tumors' named entity 'cohort study' named entity 'co-infection' named entity 'infection' named entity 'HIV-infected patients' named entity 'Physiology' named entity 'polymyositis' named entity 'HSV' named entity 'acute respiratory failure' named entity 'immunosuppressive therapy' named entity 'antimicrobial agents' named entity 'ICU' named entity 'Statistical analysis' named entity 'diagnostic methods' named entity 'HIV-infected patients' named entity 'bacterial pneumonia' named entity 'PJP' named entity 'CMV' named entity 'PJP' named entity 'mechanical ventilation' named entity 'EBV' named entity 'hematologic malignancies' named entity 'AIDS' named entity 'herpes viruses' named entity 'risk factor' named entity 'immunosuppressive therapy' named entity 'intensive care units' named entity 'PJP' named entity 'immunocompromised patients' named entity 'meningioma' named entity 'carcinoma' named entity 'heterogeneity' named entity 'ATS' named entity 'CD4 cells' named entity 'multivariate analysis' named entity 'mortality rates' named entity 'mmHg' named entity 'equivalent dose' named entity 'respiratory syncytial virus' named entity 'chemotherapies' named entity 'ICU' named entity 'HIV-infected patients'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software